The Board has an experienced multidisciplinary management and advisory team with a strong, proven record of developing and successful product commercialisation.
Mr Buttula has had extensive experience and success in investment research, funds management and information technology and has held directorships in a number of public companies. Mr Buttula’s executive experience includes co-founder and CEO and Managing Director of IWL Limited, an online financial services company that listed on the ASX in 1999. The company grew from a market capitalisation of $48 million at listing before a takeover in 2007 by Commonwealth Bank of Australia for $373 million. Mr Buttula also founded and was Managing Director of Investors Mutual, prior to which he was a co-founder and director of Lonsdale Securities Limited.
Following his completion of executive duties, Mr Buttula was Non-Executive Chairman of platform and stockbroking provider Investorfirst Limited and led the acquisition of HUB24 Limited (ASX: HUB). More recently, he served on the Board as a non-executive director and Head of Audit & Risk at Imugene Limited (ASX: IMU) between 2014 and 2016.
Chief Executive Officer
A pragmatic and commercial driven leader with over 17 years of experience in the healthcare sector across domestic and international markets. His expertise spans strategy, manufacturing and sales, with a sharp focus on disciplined execution through culture, relationships and planning. Glenn has held leadership roles at Seqirus, a CSL company (ASX:CSL), and recently at Medical Developments International (ASX:MVP) with extensive business experience across the UK, Europe, Asia, North and South America. He specialises in mergers and acquisitions, corporate development, operations, intellectual property and legal portfolios. Glenn also holds a Master of Business Administration (MBA), Graduate Certificate in Corporate Management and a Bachelor of Science degree.
Initially, Glenn’s objective is to lead the growth ambitions of Rhythm Biosciences by commercialising its pioneering ColoSTAT® technology.
A chartered accountant with extensive management experience in business and healthcare services. He is currently on the boards of ASX listed companies Sonic Healthcare Limited and Avita Medical Limited. Lou is also on the board of NeuralDX Limited and Unison Housing Limited.
Lou has more than twenty years’ experience as a board member of both public and private, for profit and not for profit companies. Previously, Lou was the CEO of Melbourne Pathology and Monash IVF, and also executive Chairman of Health Networks Australia.
Based in the United States since 2008, David is the Vice President of Business Development, North America for Bluechiip Limited. He manages Bluechiip’s operations in the US as they execute their OEM Partnership strategy to enter high value markets such as IVF and Cell Therapy. From 2014 till 2017 David was a Senior Consultant with Planet Innovation where he lead the business development efforts for the Lumos Point of Care Diagnostics Division. David has over 18 years of in-depth experience covering strategic and tactical marketing, medical device sales and the commercialisation of diagnostic products. David has previously spent three years as the Group Marketing Manager of Advanced Staining for Leica Biosystems based in Chicago. David orchestrated the integration and strategic growth of newly acquired Vision BioSystems product line within Leica’s US business unit. This was followed by three years in molecular sales for GenMark Dx where he initially covered 11 states in the US Midwest and grew his start-up territory by over 100% year on year. David’s network and contacts within the US diagnostics market can accelerate the path to commercialisation in this key geography
Trevor Lockett PhD
A molecular biologist by trade, Trevor Lockett received his PhD in biochemistry from the University of Adelaide and postdoctoral experience at the Rockefeller University in New York. With over 30 years of research experience, predominantly at the CSIRO, Trevor has led large, multidisciplinary research efforts in the areas of prostate cancer gene therapy, colorectal cancer prevention and the promotion of gastrointestinal health. In his role as Theme Leader, Colorectal Cancer and Gut Health, Trevor oversaw the research efforts leading to the technology that is to become ColoSTAT™.
Trevor is an inventor of seven active patent families, all of which have been licensed. Trevor has previously served on the leadership executive team of business units within CSIRO and has a strong commitment to improving human health and wellbeing through the translation and commercialisation of scientific discovery into innovative products and services.
Mr Vom is a Co-Founder and Executive Director of Planet Innovation, a technology development and commercialisation company, and 3 times winner of The Australian Financial Review’s Most Innovative Companies. He has a long association with RHY, being a shareholder and through his involvement as an advisor during the Company’s inception. Mr Vom has over 20 years’ experience in technology development and commercialisation in the biotech industry, having held leadership roles at cancer diagnostics manufacturer Vision BioSystems and molecular diagnostics company Genetic Technologies. He also currently serves as a non-executive director with privately owned health and wellbeing companies and is well known for his expertise in digital healthcare, management of multi discipline projects, business strategy and technology commercialisation. Mr Vom holds a Post Graduate Diploma in Management Technology and an honours degree in Industrial Engineering and Computing from Monash University.